Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
3.040
-0.110 (-3.49%)
At close: Feb 20, 2026, 4:00 PM EST
3.070
+0.030 (0.99%)
After-hours: Feb 20, 2026, 7:48 PM EST
LIXT Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
26.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLIXT News
- 4 days ago - LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - GlobeNewsWire
- 4 weeks ago - DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - GlobeNewsWire
- 4 weeks ago - LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - GlobeNewsWire
- 2 months ago - LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - GlobeNewsWire
- 2 months ago - LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities - Accesswire
- 2 months ago - LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Accesswire
- 2 months ago - LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers - Accesswire
- 3 months ago - LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment - GlobeNewsWire